Evidence map›Paper›PMID 25793507›Full record

ArticlePloS one2015

Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites.

Daniel M Dupont, Cathrine K Thuesen, Kenneth A Bøtkjær, Manja A Behrens, Karen Dam, Hans P Sørensen, Jan S Pedersen, Michael Ploug, Jan K Jensen, Peter A Andreasen

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Daniel M DupontDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark; Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Aarhus, Denmark.
Cathrine K ThuesenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark; Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Aarhus, Denmark.
Kenneth A BøtkjærDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark; Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Aarhus, Denmark.
Manja A BehrensiNANO Interdisciplinary Nanoscience Center and Department of Chemistry, Aarhus University, Aarhus, Denmark; Department of Chemistry, Lund University, Lund, Sweden.
Karen DamDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Hans P SørensenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark; Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Aarhus, Denmark.
Jan S PederseniNANO Interdisciplinary Nanoscience Center and Department of Chemistry, Aarhus University, Aarhus, Denmark.
Michael PlougDanish-Chinese Centre for Proteases and Cancer, Aarhus University, Aarhus, Denmark; Finsen Laboratory, Rigshospitalet and Biotech Research & Innovation Centre, Copenhagen, Denmark.
Jan K JensenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark; Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Aarhus, Denmark.
Peter A AndreasenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark; Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Aarhus, Denmark.
Aarhus University · DKRigshospitalet · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleic acid aptamer selection is a powerful strategy for the development of regulatory agents for molecular intervention. Accordingly, aptamers have proven their diligence in the intervention with serine protease activities, which play important roles in physiology and pathophysiology. Nonetheless, there are only a few studies on the molecular basis underlying aptamer-protease interactions and the associated mechanisms of inhibition. In the present study, we use site-directed mutagenesis to delineate the binding sites of two 2´-fluoropyrimidine RNA aptamers (upanap-12 and upanap-126) with therapeutic potential, both binding to the serine protease urokinase-type plasminogen activator (uPA). We determine the subsequent impact of aptamer binding on the well-established molecular interactions (plasmin, PAI-1, uPAR, and LRP-1A) controlling uPA activities. One of the aptamers (upanap-126) binds to the area around the C-terminal α-helix in pro-uPA, while the other aptamer (upanap-12) binds to both the β-hairpin of the growth factor domain and the kringle domain of uPA. Based on the mapping studies, combined with data from small-angle X-ray scattering analysis, we construct a model for the upanap-12:pro-uPA complex. The results suggest and highlight that the size and shape of an aptamer as well as the domain organization of a multi-domain protein such as uPA, may provide the basis for extensive sterical interference with protein ligand interactions considered distant from the aptamer binding site.

Indexed as

Aptamers, NucleotideBinding SitesCatalytic DomainHumansModels, MolecularMutagenesis, Site-DirectedScattering, Small AngleSELEX Aptamer TechniqueUrokinase-Type Plasminogen ActivatorX-Ray DiffractionAptamers, NucleotideUrokinase-Type Plasminogen Activator

Identifiers

PMID25793507
PMCPMC4368798
OpenAlexW2061068182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.